Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05835778

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Conditions: Biliary Tract Cancer

Sex: All

Healthy volunteers: No

Enrollment: 236

Sponsor: AstraZeneca

Location: Research Site Aichi

Summary

To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting.

Eligibility Criteria

Inclusion Criteria: * Patients with curatively unresectable biliary tract cancer who receive IMFINZI for the first time in combination with gemcitabine hydrochloride and cisplatin. Exclusion Criteria: \-

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05835778). StuddyBuddy aggregates publicly available trial information.